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Abstract
Stress has been implicated in the exacerbation of symptoms associated with functional lower
urinary tract disorders, such as interstitial cystitis (IC)/bladder pain syndrome (BPS) in humans.
Current research suggests a new, potential role of vascular endothelial growth factor (VEGF)
signaling in bladder dysfunction, where VEGF and associated receptors are upregulated in
bladder reflex pathways in a preclinical animal model of IC/BPS. Additional research also
associates increased VEGF expressions in the dorsal root ganglia (DRG) with pain modulation,
following CNS or PNS injury. We have examined psychogenic stress-induced expression,
function and regulation of VEGF/receptors in neural circuitry controlling the urinary bladder. A
repeated variate stress (RVS) model was used to model psychogenic stress using mice (n=6 each
for RVS-exposed and control groups). Quantitative PCR analyses were performed to determine
the expression of VEGF, VEGF receptors 1 (VEGFR1) and 2 (VEGFR2), and VEGF co-receptor
Neuropilin 2 (Nrp-2) in the bladder, lumbosacral spinal cord (L1, L2, L5, L6, S1) and
corresponding DRGs. The results demonstrate that VEGF/receptor transcripts are present in
neural pathways controlling urinary bladder function and in the urinary bladder. Regulation of
VEGF/receptor transcript expression was observed in the bladder and DRG in males exposed to
RVS, and in the spinal cord and DRG in females exposed to RVS; thereby implicating that
different parts of the micturition reflex system are more responsive to RVS. The functional role
of VEGF/receptor system in the urinary bladder was assessed using administration of a known
VEGFR2 antagonist, Ki 8751 in control and RVS-exposed mice during conscious cystometry.
No changes were observed to voiding frequency or bladder capacity for both control and RVSexposed mice after receiving Ki 8751. Functional studies suggest Ki 8751 may not be an
effective treatment to restore RVS-induced bladder dysfunction. Future studies should consider
examining the functional contribution of Nrp-2 in the VEGF/receptor system in bladder reflexes
of mice exposed to RVS. The replication of this study is also recommended in mice exposed to
prolonged RVS of at least 14 days or more.
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Introduction
Emotional and physical stress has been implicated in the exacerbation of symptoms associated
with functional lower urinary tract disorders, such as interstitial cystitis (IC)/painful bladder
syndrome (PBS) in humans. In the case of IC/PBS, these symptoms include urinary frequency,
pressure or discomfort, and pain (Merrill, 2013; Merill, 2014). This observation is supported by a
study conducted by Merrill, Malley and Vizzard which found that stressing male rats, using a
repeated variate stress model (RVS), induced an inflammatory-related change in bladder function
(i.e. increased voiding frequency), increased somatic sensitivity and increased expression of
urinary bladder nerve growth factor (NGF) (Merrill, Malley and Vizzard, 2013).
The implications of this research also allude to the association between stress and the somatic
and autonomic components of the peripheral nervous system (i.e. increased somatic sensitivity)
(Merrill, Malley & Vizzard, 2013). An investigation by Herman et al. states that the activation of
hypothalamic-pituitary-adrenal (HPA) axis, involved in stress adaptation, is followed by
corticotrophin releasing hormone (CRH) secretion by the hypothalamic paraventricular nucleus
(PVN) neurons (Herman et al., 2016). The PVN pathway is stressor dependent and its reactive
response to homeostatic disruption is inhibited by negative feedback; such that, secreted
glucocorticoids inhibit CRH neuronal activity in the PVN—among other neural mechanisms
(Herman, 2016; Herman, 2011). Based on these studies, it is possible that stress-induced bladder
inflammation originating from bladder disorders may be mediated by underlying neural circuity
influenced by the HPA axis stress response or other stress-related neural mechanisms (Merrill,
2013; Herman, 2016; Herman, 2011).
Current research about IC/PBS and other bladder diseases are geared toward identifying and
targeting protein/receptors expressed during IC/PBS to potentially identify markers of disease.
These studies also aim to identify potential targets for pharmacological intervention. Among the
proteins expressed in the urinary bladder, a member of the transient receptor potential ion
channel vanilloid family, TRPV4, is of interest. Merrill & Vizzard have determined that
exposure to RVS is associated with TRPV4 expression in the urothelium (Merrill & Vizzard,
2014). Additionally, blocking TRPV4 receptors alleviated RVS-induced bladder dysfunction
(Merrill & Vizzard, 2014). Another experiment found that the decreases in intermicurition
intervals and voided volume, induced by social stress, were restored following the inhibition of
TRPV1 channels in the bladder (Mingin et al., 2015). These studies contribute to the
understanding of the pathophysiology of the urinary bladder and provide some potential
treatments to target bladder function disorders (Merrill, 2014; Mingin, 2015).
Another protein and receptor of interest in the urinary bladder is vascular endothelial growth
factor (VEGF), which has a role in the maintenance of adult vascular function and bladder
permeability regulation. The review by Saban in 2015 describes new VEGF pathobiological
insights, including angiogenic factors, bladder neuroplasticity and IC. It is proposed that the
urinary bladder responds to injury by increasing the production of VEGF, which thereby
increases vascular permeability; evidence of permeability include glomerulations and edema
(Saban, 2015). Thus, it is believed that VEGF expression in bladder inflammation with IC/PBS
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is accompanied by angiogenic features like glomerulation (Kiuchi, 2009; Lamale, 2006; Saban,
2015; Shear 2006).
The Vizzard Research Lab has found that urinary bladder inflammation and NGF regulate the
VEGF-VEGF receptor system in rats with cyclophosphamide-induced cystitis. This finding
supports the increased expression of VEGF found in bladders that are treated with
cyclophosphamide to replicate cystitis. However, this study did not address the potential
functional role of the VEGF-VEGF receptor system in the urinary bladder (Cheppudira et al.,
2008).
Additional research demonstrates increased VEGF expression in the dorsal root ganglia (DRG)
with pain modulation, following injury to the central nervous system (CNS) or peripheral
nervous system (PNS). In a study conducted by Lindholm et al., VEGF and VEGF co-receptors
neuropilin 1 (Nrp-1) and 2 (Nrp-2) were significantly upregulated in DRG neurons following
dorsal root injury in the PNS (Lindholm et al., 2017). This study suggests a potential role for
VEGF and neuropilins in the lumbar DRG in response to dorsal root injury, which is associated
with neuropathic pain. Another researcher demonstrated that VEGF activity influences the level
of a pain-related neuropeptide in lumbar DRG (L1-L6) upon injuring intervertebral discs (Sato et
al., 2017). Sato et al. found that the inhibition of VEGF expression by an anti-VEGF drug
reduces the expression of the neuropeptide (Sato et al., 2017). Collectively, these studies
demonstrate that VEGF/receptors signaling pathways are present in the neural pathways that
respond to injury in the CNS or PNS (Lindholm, 2017; Sato, 2017).
Based on current studies, VEGF expression is evident by inducing the urinary bladder (drugbased) to reproduce cystitis. VEGF is also implicated with angiogenic factors and bladder
neuroplasticity (Saban, 2015). Additional research suggests VEGF/receptor activity and pain
modulation involving the dorsal root ganglia, occurs following CNS or PNS injury (Lindholm,
2017; Sato, 2017). Examining the role of VEGF as it relates to stress, bladder dysfunction and
angiogenesis may introduce a new understanding of the urinary bladder pathophysiology.
Furthermore, it could aid in the development of clinical treatments for functional lower urinary
tract disorders. Thus, these experiments seek to determine the effects of psychogenic stress on
the expression, function and regulation of VEGF and its receptors in the neural circuity
controlling the urinary bladder.
In these experiments, a repeated variate stress (RVS) animal model will be used to replicate
symptoms of interstitial cystitis, including bladder overactivity and bladder inflammation.
Previous research using RVS has observed changes to the micturition reflex function, including
decreased bladder capacity, decreased void volume and increased urinary frequency in rats
(Merrill & Vizzard, 2014). These changes are associated with bladder overactivity and cystitis.
In this study, adult male and female mice will be exposed to a single stressor each day for a
period of seven days of RVS. The urinary bladders will be harvested and Quantitative PCR
analyses will be performed to determine VEGF, and VEGF receptor (VEGFR1, VEGFR2, Nrp2) expression in both control mice and RVS-exposed mice. It is hypothesized that exposure to
RVS will result in an increased voiding frequency and will alter the expression of VEGF and its
receptors relative to the control group. We will also determine if the pharmacological blockade
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of VEGF receptors, using a commercially available VEGF receptor antagonist, will improve
bladder function after RVS using conscious cystometry.
*Please note: The term stress will also be used when references are made to the use of RVS in
this research study (i.e. “stress female” is equivalent to “females exposed to RVS”).
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Methods
Mice. Adult, male and female mice, from an in-house colony were placed in colony cages (3-4
mice per cage; N = 48). Animal use procedures were approved by the University of Vermont
Institutional Animal Care and Use Committee (Protocols 08-055 and 13-030). The National
Institutes of Health Guide for the Care and Use of Laboratory Animals was referenced to
perform animal experimentation.
Repeated Variate Stress. Mice were randomly assigned to control or RVS groups (n=6 per
treatment group). RVS-exposed mice were subjected to seven days of stress, during which, they
were exposed to one stressor each day. Mice were weighed on Day 0 to establish a baseline
weight and every day of RVS prior to stress exposure (Day 1-7). Control mice were housed in
their home cage in the animal facility and were only handled for weight measurement.
Oscillation stress. Mice were placed into a plastic chamber 28 x 17 x 13 cm (L x W x H)
that was connected to a clinical rotator (Fisher Scientific, Morris Plains, NJ) and
oscillated for 30 min at low to medium speed.
Forced swim. Mice were placed into a cylindrical container 29 x 37 cm (D x H) filled
with room temperature water (37C). The water was maintained at a depth that prevented
the mouse’s tail from touching the bottom of the container. Mice swimming was
monitored for 5 min followed by 30 min of rest in a holding chamber before returning to
their home cage.
Electrical footshock. Mice were acclimated inside a Plexiglas conditioning chamber 30 x
25 x 35 cm (L x W x H) (Med Associates, St. Albans, VT) for 5 min. Mice were then
given two sets of 1.0 mA 5 sec footshocks with a 1-min intertrial interval. The footshock
was delivered through the grid floor.
Restraint. Mice were placed into a cylindrical restraining device 9 x 15 cm (D x H) for 60
min.
Pedestal. Mice were placed onto an elevated platform (60 cm above floor) 20 x 20 cm (L
x W) for 30 min.
Refer to Merrill, Malley & Vizzard for additional RVS protocol details (2013).
Tissue Collection. Control and RVS-exposed mice were euthanized 24 hours after the last
stressor by anesthetization with isoflurane in oxygen (3-4%) followed by euthanasia via
thoracotomy. The urinary bladder, lumbosacral spinal cord (L1-L6, S1) and corresponding DRG
(L1-L6, S1) were dissected in RNase-free conditions. The bladder was cut across the midline and
pinned to a sylgard-coated dish to separate the urothelium from detrusor smooth muscle, using
fine forceps and a dissecting microscope. All tissues were snap-frozen on dry ice and stored in 80 ˚C freezer prior to preparation for real-time quantitative reverse transcription-polymerase
chain reaction (QPCR).
Real-Time Quantitative Reverse Transcription-Polymerase Chain Reaction (QPCR). QPCR was
used to determine the transcript level of VEGF and its receptors in the urinary bladder
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(urothelium, detrusor), lumbosacral spinal cord (L1-L6, S1) and DRG in control and RVSexposed mice (n=6 for each group). The total RNA was extracted using STAT-60 total
RNA/mRNA isolation reagent (Tel-Test ‘B’, Friendswood, TX, USA). Complementary DNA
with a final reaction volume of 25 µl was synthesized using a mix of random hexamer, oligo dT
primers and M-MLV reverse transcriptase (Promega Corp.) with one microgram of RNA per
sample. Amplified cDNA products were ligated into pCR2.1 TOPO vector using the TOPO TA
cloning kit (Invitrogen) to prepare the quantitative PCR standards for all transcripts. The
nucleotide sequences for the inserts were confirmed using an automated fluorescent dideoxy dye
terminator sequencing (Vermont Cancer Center DNA Analysis Facility). A 10-fold serial
dilution of stock plasmids were used as quantitative standards to determine the relative
expression of receptor transcripts. The standard concentrations range was empirically deduced.
Complementary DNA templates were diluted 10-fold to reduce inhibitory effects of the reverse
transcription constituents. The final reaction volume of 25 µl comprised an assay of cDNA using
Luna Universal qPCR Master Mix (Ipswich, MA, USA) and 300 nM of each primer.
The Q-PCR was conducted using an Applied Biosystems 7500 Fast real-time PCR system
(Applied Biosystems, Foster City, CA, USA) under the following standard conditions: (1) serial
heating at 95°C for 2 min and (2) amplification over 45 cycles at 95°C for 15 sec and 52-64°C
depending on primers set for 30 sec. SYBR Green I melting analysis was incorporated into the
amplified production within these amplification parameters by increasing the temperature of the
reaction samples from 60 to 95°C. A single DNA melting profile was generated from this
dissociation assay condition to produce a single, pure product—free of primer dimers or other
sources of contamination.
The standard curve generated through the amplification of the serially diluted plasmids
containing the target sequence was used for data analyses. The Sequence Detection Software,
version 1.3.1 (Applied Biosystems, Norwalk, CT, USA) was used to detect sequencing after each
assay was completed. Default baseline settings were used for standard assays. The increase of
SYBR Green I fluorescence intensity (ΔRn) was plotted as a function of cycle number. The
threshold cycle, as determined by the software, was set as the amplification cycle where ΔRn
first intersects the predetermined baseline. The data is expressed as a relative quantity of the gene
of interest normalized to the relative quantity of the housekeeping gene actin or 18S. Control
samples are set equal to 100%.
Intravesical Catheter Implant. Male and female mice (n=6 per treatment group) received
preoperative analgesics (carprofen, 5.0 mg/kg, s.c.) and were placed under anesthesia with
isoflurane in oxygen (3-4%). An incision was made to the midline of the lower abdomen and
polyethylene tubing (PE-10, Clay Adams, Parsippany, NJ, USA) was inserted into the bladder
dome; which was secured with nylon purse-string sutures (6-zero) using the technique described
by Guo et al., Schengelsberg et al., and Gonzalez et al. (2018; 2010;2013). Following surgery,
mice were administered postoperative analgesics (carprofen, 5.0 mg/kg, s.c.) every 24 h for a
total of 48 h.
Conscious, Open Outlet, Continuous Fill Cystometry. Cystometry was performed in conscious
male and female mice (control, RVS). An unrestrained animal with an empty bladder was
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transferred to a Plexiglass cage with a wire bottom. The intravesical catheter was attached to a Ttube, which was connected to a pressure transducer (Grass Model PT300, West Warwick, RI,
USA) and microinjection pump (Harvard Apparatus 22, South Natick, MA, USA). Urodynamic
measurements were collected by a Small Animal Cystometry Lab Station (MED Associates, St.
Albans, VT, USA) as described by Guo et al., Schengelsberg et al., and Gonzalez et al. (2018;
2010;2013). Repetitive bladder contractions were generated with saline solution, infusing at
room temperature into the bladder at a rate of 25 μl/min. Once an initial stabilization period of
25-30 minutes was established, at least six reproducible micturition cycles were measured. The
cystometric parameters recorded in each animal were as follows: minimum pressure (pressure at
the start of the bladder filling), threshold pressure (bladder pressure immediately before
micturition), maximum micturition pressure, intercontraction interval (time between micturition
events), infused volume, void volume, presence and amplitude of non-voiding bladder
contractions (NVCs; Guo et al., 2018; Schengelsberg et al., 2010; Gonzalez et al., 2013). NVCs
constituted rhythmic intravesical pressure increases that were 5 cm H 20 above baseline that took
place during the filling phase without fluid release from the urethra. The infused volume was
determined by the volume of saline infused into the bladder when micturition began. Note,
infused volume and void volume were similar as the mice from these studies had residual
volumes of less than 5 μl. Following the completion of this experiment, mice were euthanized
using 5% isoflurane and thoracotomy.
Conscious Cystometry and Effects of Ki8751, a Potent and Selective VEGFR2 Antagonist. The
effects of Ki8751, a potent and selective VEGFR2 antagonist (Tocris Bioscience, Minneapolis,
MN, USA), on the urinary bladder function of WT male and female mice (control, RVS) were
observed using a conscious, open outlet, cystometry with a continuous incremental flow of
intravesical saline (0.9%; Guo et al., 2018; Schengelsberg et al., 2010; Gonzalez et al., 2013).
The intravesical volume of Ki8751 was inserted in anesthetized (2% isoflurane) mice. The
Ki8751 treatment was injected through the bladder catheter; and the animal subsequently
remained under anesthesia for 30 minutes to avoid Ki8751 expulsion from voiding reflex. The
treatment remained in the bladder for the duration of this step, after which, the bladder was
washed with saline (0.9%). Prior to continuing experimentation, the animals recovered for 20
minutes first breathing oxygen (100%) followed by room air. Cystometry experiments monitored
micturition patterns derived from before and after vehicle or after intravesical administration of
Ki8751.
Following the completion of these studies, mice were euthanized using 5% isoflurane and
thoracotomy. These experiments were performed during similar times of the day to limit possible
circadian variations derived from changes in cystometric measurements. The cystometric data
was analyzed by individuals who were blind to the treatment groups, and was later decoded (Guo
et al., 2018; Schengelsberg et al., 2010; Gonzalez et al., 2013).
Statistical Analyses. One-way analysis of variance (ANOVA) were used to assess for differences
between groups for QPCR. Paired t-tests were also used to assess QPCR and cystometry-derived
data. All statistical analyses were performed using GraphPad Prism 7.01. Differences were
considered statistically significant if p ≤ 0.05.
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Data Analyses. Data interpretation of QPCR was limited to examining differences in expression
and regulation (1) between control and stress tissue and (2) between male and female mice; and
(3) basal levels of expression in tissue levels. Data interpretation of cystometry was limited to
examining (1) change to bladder function before and after the administration of VEGFR2
blockade, and (2) differences between male and female bladder function.
Results
Figure 1. Summary diagram of central and peripheral micturition
reflex pathways. We examined sections of spinal cord and
corresponding DRG at levels L1, L2, L6 and S1 where known
peripheral nerves project to innervate the urinary bladder in mice.
Also note L5 served as the control given nerves from this level do
not innervate or influence the micturition reflex.
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Figure 2. Quantification of VEGF/receptor transcript levels in male control and RVS urinary bladder, which was
split into urothelium and detrusor. (A) Difference in VEGF transcript levels is significantly higher in control
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Table 1. Summary of Regulation of
VEGF/Receptors in male Urinary Bladder.

Protein

Urothelium

Detrusor

VEGF

-

-

VEGFR1

-

-

VEGFR2

-

-

Nrp-2

-

↑

urothelium compared to control detrusor, but does not reach
statistical significance between control and stress groups. *, p
≤ 0.05 n=6; (B) Significant increase in VEGFR1 expression
in control urothelium compared with control detrusor. There is
insignificant change in transcript expression between control
and stress tissues. *, p ≤ 0.05 n=6; (C) Significantly higher
VEGFR2 transcript expression evident in control urothelium
in comparison to control detrusor, but otherwise negligible
difference in transcript levels between treatment groups. *, p ≤
0.05 n=6; (D) Nrp-2 transcript expression is significantly
upregulated in stress detrusor. Negligible change in Nrp-2
mRNA expression observed between stress and control
urothelium. There are significantly increased transcript levels
in control detrusor compared to control urothelium. *, p ≤ 0.05
n=6

Effects of RVS on Urinary Bladder in Male Mice via qPCR
To assess whether exposure to RVS changes VEGF/receptor transcript expression in the urinary
bladder, q-PCR analyses were performed on stress and control male mice. In each group, the
urinary bladder was split into the urothelium and detrusor tissue layers. The VEGF transcript
levels between the control and stress urinary bladder did not reach statistical significance (Fig.
2A). Basal level VEGF expression was significantly higher in the urothelium when compared to
detrusor smooth muscle. Similarly, transcript expression of VEGFR1 was negligible between
control and stress bladder tissue (Fig. 2B). Additionally, VEGFR1 transcript levels were
significantly increased in control urothelium compared to control detrusor.
For VEGFR2, the receptor mRNA expression was insignificant between control and stress
tissues of the urinary bladder (Fig. 2C). That said, VEGFR2 was shown to have significantly
higher basal level expression in the urothelium relative to the detrusor.
The expression of VEGF co-receptor Nrp-2 was significantly increased in stress detrusor (Fig.
2D, Table 1). Additionally, negligible change in Nrp-2 mRNA expression was observed for
stress and control urothelium. The basal level expression of Nrp-2 was increased in the detrusor
compared to urothelium.
In addition, VEGF, VEGFR1 and VEGFR2 were notable for higher basal level of expression in
the urothelium compared to the detrusor. In contrast, levels of Nrp-2 transcript levels were
greater in the control and stress detrusor layers compared to the urothelium.

10

3B

2.5
2
1.5
1
0.5
0

SC L1

SC L2

SC L5

SC L6

VEGFr2 relative quantity /
18S relative quantity
(Fold Change over SC L1 Ctl)

Control
Stress

3
2.5
2
1.5
1
0.5
0

SC L1

SC L2

SC L5

SC L6

1.5
1
0.5

SC S1

3C

3D

0

SC L1

SC L2

*

5

SC L5

*

*

SC L6

SC S1
Control
Stress

4
3
2
1
0

SC S1

Control
Stress

2

VEGFr1 relative quantity /
18S relative quantity
(Fold Change over SC L1 Ctl)

Control
Stress

3

Nrp-2 relative quantity /
18S relative quantity
(Fold Change over SC L1 Ctl)

VEGF relative quantity /
18S relative quantity
(Fold Change over SC L1 Ctl)

3A

SC L1

SC L2

SC L5

SC L6

SC S1

Figure 3. Quantification of VEGF/receptor transcript levels in male control and RVS spinal cord (SC) at levels: L1,
L2, L5, L6 and S1. (A) VEGF transcript expression between control and stress tissues of spinal cord does not reach
statistical significance. *, p ≤ 0.05 n=6; (B) Differences in the expression of VEGFR1 between control and stress
spinal cord is insignificant. *, p ≤ 0.05 n=6; (C) VEGFR2 expression between control and stress spinal cord is not
statistically different. *, p ≤ 0.05 n=6; (D) Basal level Nrp-2 transcript expression is statistically significant between
control SC L1 and L5; L2 and L5; and L5 and S1. There is negligible change between control and stress Nrp-2
expression in spinal cord. *, p ≤ 0.05 n=6

Effects of RVS on Spinal Cord in Male Mice
The effects of RVS on VEGF/receptor transcript expression in the spinal cord of control and
stress male mice were examined by performing q-PCR analyses. Each group consisted of L1, L2,
L5, L6 and S1 spinal cord levels. The expression of the VEGF protein was not significant
between control and stress spinal cord (Fig. 3A). However, there was an increasing trend of
VEGF mRNA expression in stress tissue at L5 and S1. Stress spinal cord at levels L1, L2 and L6
exhibited a decreasing trend of VEGF transcript levels. For VEGFR1, the difference in transcript
expression between control and stress spinal cord was insignificant (Fig. 3B). That said, a
decreasing trend of VEGFR1 transcript levels was evident in stress L1 and L5; negligible
differences of transcript expression were observed in L2 and L6. An upward trend of receptor
mRNA expression was observed in stress S1. Differences in VEGFR2 transcript expression
between control and stress spinal cord did not reach statistical significance (Fig. 3C). However,
there was an increasing trend of VEGFR2 expression observed in stress tissue at levels L2 and
S1; negligible change of VEGFR2 expression was evident between control and stress L1 and L5.
There was a downward trend in stress L6 for VEGFR2 mRNA levels.
Nrp-2 also presented insignificant changes of transcript levels between stress and control spinal
cord (Fig. 3D). An upward trend of Nrp-2 transcript expression was visible in stress L2, L5 and
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S1. Nrp-2 showed a decrease trend of expression in stress L6; and negligible change in L1. There
were statistically significant differences in Nrp-2 expression between different levels of control
spinal cord, including L1 and L5; L2 and L5; and L5 and S1. In summary, the changes in the
transcript expression of VEGF/receptors between control and stress spinal cord did not reach
statistical significance. Of note, the expression of Nrp-2 exhibited significant differences at the
basal level of several spinal cord sections, showing that there was higher basal level of Nrp-2
expression in L5 compared to L1, L2, and S1.
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Figure 4. Quantification of VEGF/receptor transcript levels in male control and RVS dorsal root ganglia (DRG) at
spinal cord levels L1, L2, L5, L6 and S1. (A) VEGF transcript expression is downregulated in stress DRG L1, L2
and L5. Basal level VEGF expression is statistically significant between control DRG L2 and L6, and L5 and L6. p
≤ 0.05 n=6; (B) VEGFR1 transcript expression is downregulated in stress DRG L1, L2, and L6. Significant
differences observed in basal level expression of VEGFR1 between control DRG L1 and L5; L1 and L6; and L1 and
S1. *, p ≤ 0.05 n=6; (C) VEGFR2 transcript expression is downregulated in stress DRG L2 and L5. Significant
variance of basal transcript expression was exhibited between control DRG L1 and L5; L2 and S1; L5 and L6; and
L6 and S1.*, p ≤ 0.05 n=6; (D) Nrp-2 transcript levels were downregulated in stress DRG L1, L2, L5 and L6.
Comparison between basal levels showed significant difference of Nrp-2 expression between control DRG L1 and
L5; L1 and S1; L2 and L5; and L2 and S1. *, p ≤ 0.05 n=6
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Protein

L1

L2

L5

L6

S1

VEGF

↓

↓

↓

-

-

VEGFR1

↓

↓

-

↓

-

VEGFR2

-

↓

↓

-

-

Nrp-2

↓

↓

↓

↓

-

Table 2. Summary of Regulation of
VEGF/Receptors in male dorsal root
ganglia.

Effects of RVS on Dorsal Root Ganglia in Male Mice
To determine if exposure to RVS effects the mRNA levels of VEGF/receptors in the dorsal root
ganglia, we performed q-PCR analyses in control and stress male mice. For each group, we
examined DRGs that corresponded to the same levels of the spinal cord we assessed previously:
L1, L2, L5, L6 and S1. We found that VEGF transcript levels were significantly lower in stress
DRG L1, L2 and L5 (Fig. 4A, Table 2). Additionally, basal levels of VEGF expression were
significantly higher in DRG L2 and L5 when these levels were compared to L6.
A significant decrease in transcript expression was also observed for VEGFR1 in stress DRG
L1, L2 and L6 (Fig. 4B, Table 2). Furthermore, control DRG L1 was notable for increased
VEGFR1 basal level expression when compared to control DRG L5, L6 and S1. For VEGFR2,
stress DRG L2 and L5 exhibited significantly lower receptor transcript levels (Fig. 4C, Table 2).
Control DRG L5 exhibited increased baseline expression relative to control DRG L1, L6 and S1.
Likewise, basal levels of VEGFR2 expression was significantly higher in DRG L2 in comparison
to S1.
The Nrp-2 transcript levels were significantly decreased in stress DRG L1, L2 L5 and L6 (Fig.
4D, Table 2). A comparison between basal levels showed significant increase in DRG L1 and L2
when compared to both L5 and S1. Overall, VEGF, VEGFR1, VEGFR2 and Nrp-2 mRNA levels
were found to be significantly lower in certain DRG stress tissues. Additionally, basal level
expressions of VEGF/receptors were notably higher in DRG L1, L2 and L5; and lower in L6 and
S1.
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Figure 5. Quantification of VEGF/receptor transcript levels in female control and RVS urinary bladder; split into
urothelium and detrusor. (A) Significantly higher VEGF transcript levels in control urothelium relative to control
detrusor. Insignificant difference between control and stress groups. *, p ≤ 0.05 n=6; (B) Significant increase in
VEGFR1 expression in control urothelium compared with control detrusor. There is no remarkable change in
mRNA levels between control and stress tissues. *, p ≤ 0.05 n=6; (C) Significantly higher VEGFR2 transcript
expression is exhibited by control urothelium compared to control detrusor, but otherwise negligible difference in
transcript levels between treatment groups. *, p ≤ 0.05 n=6; (D) There are no statistical differences in Nrp-2
transcript expression between control and stress tissues. *, p ≤ 0.05 n=6

Effects of RVS on Urinary Bladder in Female Mice
VEGF/receptor transcript expression within the RVS paradigm was examined using q-PCR
analyses on stress and control female bladders. There were no statistically significant differences
in VEGF expression observed between control and stress bladder (Fig. 5A). Basal level
expressions of the protein were significantly higher in the urothelium relative to detrusor.
Similarly, the transcript expression of VEGFR1 was negligible between control and stress
bladder (Fig. 5B). That said, basal levels of VEGFR1 were notably higher in the urothelium
compared to detrusor.
For VEGFR2, the receptor mRNA expression was insignificant between the treatment groups
(Fig. 5C). However, similar to VEGF and VEGFR1, basal transcript levels of VEGFR2 were
significantly higher in the urothelium when compared to the detrusor. Overall, VEGF and its
immediate receptors (R1 and R2) exhibited higher basal level expression in the urothelium.
Lastly, the expression of Nrp-2 did not reach statistical significance between control and stress
bladder (Fig. 5D). Higher Nrp-2 transcript expression was observed in the detrusor relative to
detrusor.
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Figure 6. Quantification of VEGF/receptor transcript levels in female control and RVS spinal cord (SC) at levels:
L1, L2, L5, L6 and S1. (A) VEGF transcript expression is downregulated in stress SC L1. Otherwise, there are
negligible differences between the control and stress tissues, such that statistical significance is not achieved. *, p ≤
0.05 n=4-6; (B) Significant decrease of VEGFR1 expression observed in stress SC L1 and L2. Receptor transcript
expression is upregulated in stress SC L6 and S1. Significant differences observed in basal level expression of
VEGFR1 between control SC L1 and L6; L1 and S1; L5 and L6; L5 and S1.*, p ≤ 0.05 n=4-6; (C) VEGFR2
expression is downregulated in stress SC L2 and upregulated in stress L6. Otherwise, control and stress SC do not
reach statistical significance. *, p ≤ 0.05 n=4-6; (D) Nrp-2 transcript expression is downregulated in stress SC L1
and L2. Receptor transcript levels are upregulated in stress SC L6. Basal level expression in SC L5 is significantly
different from L6. *, p ≤ 0.05 n=4-6

Protein

L1

L2

L5

L6

S1

VEGF

↓

-

-

-

-

VEGFR1

↓

↓

-

↑

↑

VEGFR2

-

↓

-

↑

-

Nrp-2

↓

↓

-

↑

-

15

Table 3. Summary of Regulation of
VEGF/Receptors in female spinal cord.

Effects of RVS on Spinal Cord in Female Mice
The implications of RVS on VEGF/receptor transcript expression in the spinal cord of control
and stress female mice were examined by performing q-PCR analyses. Each group comprised
L1, L2, L5, L6 and S1 spinal cord levels. VEGF expression was significantly decreased in stress
L1 (Fig. 6A, Table 3). Otherwise, there were negligible differences between the remaining
control and stress groups, and across the spinal cord levels. The mRNA levels of VEGFR1 were
significantly lower in stress L1 and L2 (Fig. 6B, Table 3). Additionally, receptor transcript
expressions were significantly increased in stress L6 and S1. The basal level expression of
VEGFR1 was higher in control L1 and L5 when compared to L6 and S1. Of note, VEGFR2
mRNA levels exhibited significantly lower expression in stress L2 and higher expression in
stress L6 (Fig. 6C, Table 3). However, the remaining control and stress groups exhibited
negligible change and thus, did not reach statistical significance.
Nrp-2 transcript levels significantly decreased in stress L1 and L2 (Fig. 6D, Table 3). In addition,
the co-receptor expression was significantly higher co-receptor expression in stress L6. In
summary, the expression of the VEGF protein only decreased in stress L1 in response to RVS. In
addition to this, the primary receptors (R1 and R2) and the co-receptor (Nrp-2) dually exhibited
both higher receptor expression in the lower spinal cord levels L6 and/or S1 and lower
expression in L1 and/or L2 in response to RVS.
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Figure 7. Quantification of VEGF/receptor transcript levels in female control and RVS dorsal root ganglia (DRG) at
spinal cord levels L1, L2, L5, L6 and S1. (A) There are negligible differences between control and stress tissue and
thus, statistical significance is not achieved. Basal level expression of VEGF in DRG S1 is significantly higher
relative to L1 and L2. *, p ≤ 0.05 n=4-6; (B) VEGFR1 mRNA levels are upregulated in stress DRG L6. There is
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significantly higher VEGFR1 expression in control DRG S1 relative to controls L5 and L6. *, p ≤ 0.05 n=4-6; (C)
There are no significant differences in VEGFR2 transcript expression between control and stress tissues. *, p ≤ 0.05
n=4-6; (D) Nrp-2 expression is downregulated in stress DRG S1, but otherwise control and stress DRG do not reach
statistical significance. *, p ≤ 0.05 n=4-6
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Table 4. Summary of Regulation of
VEGF/Receptors in female dorsal root
ganglia.

Effects of RVS on Dorsal Root Ganglia in Female Mice
A series of q-PCR analyses were performed to assess RVS effects on the mRNA levels of
VEGF/receptors in the DRG of control and stress female mice. For each group, we examined
DRGs that corresponded to the same levels of the spinal cord that were assessed previously: L1,
L2, L5, L6 and S1. We found that VEGF transcript levels did not reach statistical significance
between control and stress DRG (Fig. 7A). That said, basal levels of VEGF expression were
significantly higher in control DRG S1 when compared to L1 and L2. In VEGFR1, receptor
transcript levels were significantly increased in stress DRG L6 (Fig. 7B, Table 4). In addition,
there was a significantly higher receptor expression in control DRG S1 relative to controls L5
and L6. For VEGFR2, there was negligible differences in receptor expression between control
and stress DRG (Fig. 7C).
The Nrp-2 transcript levels were significantly lower in stress DRG S1 compared to its
corresponding control group (Fig. 7D, Table 4). Apart from this finding, there were insignificant
changes in Nrp-2 expression between the control and stress DRG. In summation, VEGFR1 and
Nrp-2 were responsive to RVS in the DRG tissue, specifically in L6 and S1 levels respectively.
To add to that, the effect of RVS on the expression of both VEGF and VEGFR2 was
insignificant. Additionally, basal level of expression between the spinal cord levels varied, such
that there was an overall higher VEGF and VEGFR1 expression in DRG S1 receptor expression
in DRG S1.
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Cystometry Analysis of Urinary Bladder Function with Ki 8751: RVS and Control Mice
Figure 8. Summary bar graphs
representing pressures measured
from open cystometry of
conscious, unrestrained male
mice. No significant changes (p ≥
0.05) to threshold, minimum,
average or maximum pressure
observed in control and RVSexposed mice following infusion
of Ki 8751, known
pharmaceutical VEGFR2
blocker. Data shows mean +/SEM of n=4-6 mice per group.

Figure 9. Summary bar graphs
representing pressures measured
from open cystometry of
conscious, unrestrained female
mice. No significant changes (p ≥
0.05) to threshold, minimum,
average or maximum pressure
observed in control and RVSexposed mice following infusion
of Ki 8751, known
pharmaceutical VEGFR2 blocker.
Data shows mean +/- SEM of
n=4-6 mice per group.

*
*

Figure 10. Summary bar graphs
representing infused volume (IV)
measured from open cystometry
of conscious, unrestrained (A)
male and (B) female mice. No
significant changes (p ≥ 0.05) to
IV observed in control and RVSexposed mice (A, B) following
infusion of Ki 8751, known
pharmaceutical VEGFR2
blocker. Data shows mean +/SEM of n=4-6 mice per group.
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Figure 11. Summary bar
graphs representing
intermicturition interval
(II) measured from open
cystometry of conscious,
unrestrained (A) male and
(B) female mice. No
significant changes (p ≥
0.05) to II observed in
control and RVS-exposed
mice (A, B) following
infusion of Ki 8751. Data
shows mean +/- SEM of
n=4-6 mice per group.

Figure 12. Summary bar
graphs representing void
volume (VV) measured
from open cystometry of
conscious, unrestrained
(A) male and (B) female
mice. No significant
changes (p ≥ 0.05) to VV
observed in control and
RVS-exposed mice (A, B)
following infusion of Ki
8751. Data shows mean
+/- SEM of n=4-6 mice
per group.

Figure 13. Sample cystometrogram traces from a conscious, unrestrained female control mouse. Figure reflects
minimum pressure (1), threshold pressure (2), maximum pressure (3), intermicturition intervals (4), and infused
volume (5) selected from a section of the pre-infusion phase, prior to infusing VEGFR2 blockade, Ki 8751. Note:
Average pressure is not depicted as it reflects a collective average of minimum pressure, threshold pressure and
maximum pressure. Void volume is also not shown.
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In this research study, we examined the functional role of the VEGF/receptor system in urinary
bladder inflammation in male and female mice. Conscious cystometry was performed in control
and RVS-exposed mice who were monitored and kept unrestrained in the cystometrogram. A
pre-infusion phase was established to allow for acclimation to the chamber, which was followed
by an infusion phase in which Ki 8751, a known VEGFR2 antagonist was administered over a
period of 30 minutes. A post-infusion phase was then carried out to observe bladder activity.
Refer to Figure 13 for depiction of voiding reflexes and factors used to quantify the bladder
response to continuous infusion of saline. Ki 8751 did not alter bladder function under normal
conditions. In control male mice, there were no changes observed to intermicturition intervals,
void volume, infused volume, micturition threshold pressure or maximum voiding pressure (Fig.
8, 10A, 11A, 12A). However, there was a decrease to baseline pressure observed (Fig. 8).
Collectively, there were no changes observed in voiding frequency and minimal changes to
bladder capacity in urinary bladders of control male mice following VEGFR2 blockade. For
stress mice, the administration of Ki 8751 similarly did not alleviate or alter bladder function.
There were no changes to void volume and intermicturition intervals, suggesting that Ki 8751
did not alter void frequency (Fig. 11A, 12A). Negligible changes were seen from the infused
volume, baseline pressure, micturition threshold pressure, or maximum voiding pressure were
seen (Fig. 8, 10A). Thus, there were no modifications to the voiding pattern observed in male
mice exposed to repeated variate stress.
In the control female group, threshold pressure and maximum pressure were significantly
reduced, suggesting a possible effect of the drug to bladder capacity within a normal functioning
bladder (Fig. 9). However, there were no modifications seen to infused volume or baseline
pressure, which are other measures of bladder capacity (Fig. 9, 10B). The inconsistency of
results that described bladder capacity make it difficult to confirm whether the infusion of Ki
8751 directly contributed to changes observed in the threshold pressure and maximum pressure.
Thus, further exploration is recommended to confirm the role of Ki 8751 to this change. The
void volume and intermicturition intervals were unchanged and thus, voiding frequency was not
altered (Fig. 11B, 12B). Restoration to bladder dysfunction was not evident in female mice
exposed to RVS following Ki 8751 infusion. No change to void frequency, such that negligible
changes were seen to the intermicturition intervals and void volume between pre and post Ki
8751 infusion phases (Fig. 11B, 12B). Furthermore, bladder capacity did not change with R2
antagonist, which included insignificant changes to infused volume, baseline pressure,
micturition threshold pressure, or maximum voiding pressure (Fig. 9, 10B).
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Discussion
Expression & Regulation of VEGF/receptor in the Neurogenic Bladder
These experiments examined how chronic variate stress-induced cystitis affected the
VEGF/receptor system in the neural pathways controlling the urinary bladder, and the urinary
bladder, in male and female mice. In response to RVS, results demonstrate that co-receptor Nrp2 is upregulated in male detrusor smooth muscle. Additionally, there was negligible change in
the activity of VEGF and its primary receptors in the urinary bladder between the male control
and stress groups. This finding suggests that Nrp-2 responds to RVS in male mice, however, the
stress paradigm does not regulate the expression of VEGF, VEGR1 or VEGFR2 in the urinary
bladder. Contrary to this observation, in female mice, VEGF and its receptors were not affected
by—and thereby were not responsive to—exposure to RVS. Of note, in both sexes there were
higher basal expressions of VEGF and its primary receptors in the urothelium. Additionally,
Nrp-2 was more highly expressed at basal levels in the detrusor in male and female mice. Thus,
this study also confirmed that there is a difference in the expression of VEGF and its receptors
between the layers of the urinary bladder in wild type mice.
In male spinal cords, VEGF/receptor regulation was not demonstrated following exposure to
chronic variate stress. In females, the expression of the VEGF protein and VEGFR1 were
downregulated in L1 following RVS exposure. Downregulation was also observed in all VEGF
receptors (VEGFR1, VEGFR2, Nrp-2) in stress L2. Concomitantly, these receptors were also
upregulated in stress L6. Overall, VEGFR1 appears to be the most responsive receptor to RVS in
female mice, which also exhibited upregulation in stress S1. In summary, our results demonstrate
the responsiveness of the VEGF/receptor system to RVS is limited to female mice.
In male DRGs, VEGF was downregulated in stress L1, L2 and L5. Similarly, VEGFR1 exhibited
downregulation in stress L1 and L2. Unlike VEGF, however, this receptor was also
downregulated in stress L6. Co-receptor Nrp-2 showed the greatest distribution of
downregulation across the spinal cord levels with decreased expression in stress L1, L2, L5 and
L6. We thereby demonstrate that the VEGF/receptor system responds to chronic variate stress in
the male lumbosacral DRGs. In general, a pattern of downregulation of VEGF/receptor transcript
expression was seen at various levels of stress male DRG. That said, this pattern was not
observed in female mice. For example, VEGFR1 was upregulated in stress L6 while Nrp-2 was
downregulated in the same level. Hence, while the regulation of the VEGF receptors is present in
female DRG, the type of regulation varies depending on the specific receptor observed. This
observation was not demonstrated in female VEGF and VEGFR2, which were not responsive to
RVS in the DRG. In summary, these results suggest that the regulation of VEGF and its
receptors occurs in stress male bladder and dorsal root ganglia; and the regulation of the
VEGF/receptor system in female mice is limited to stress spinal cord and dorsal root ganglia.
In the past, the function of VEGF has been associated with the maintenance of adult vascular
function (i.e. blood vessel formation) and the regulation of bladder permeability (Saban, 2015).
Current research ascribes new pathobiological roles for VEGF, paralleling increased VEGF
production with angiogenic factors, bladder neuroplasticity and interstitial cystitis. Regarding
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cystitis, Saban’s review from 2015 proposes that an increased production of VEGF exemplifies
the urinary bladder’s response to injury and inflammation (Saban, 2015). Moreover, a previous
study in the Vizzard Research lab finds that VEGF production was upregulated in bladders
treated with cyclophosphamide (Cheppudira et al., 2008). Our study partially supports the
conclusions derived from past research studies. While co-receptor Nrp-2 was upregulated in
male mice, VEGF and its primary receptors were not responsive to RVS-induced bladder
inflammation in male and female mice. Thus, findings from both Saban and Cheppudira et al.
describe a different response to bladder inflammation by the VEGF/receptor system compared to
the results drawn from our current research study (Saban, 2015; Cheppudira et al., 2008). In
terms of the neural circuitry underlying the urinary bladder, Lindholm and Sato found that VEGF
expression increases in the dorsal root ganglia with pain modulation, following injury to the
central nervous system (CNS) and peripheral nervous system (PNS) (Lindholm, 2017; Sato,
2017). In contrast to these studies, this study demonstrates downregulation in male dorsal root
ganglia and variable regulation in female dorsal root ganglia, following exposure to repeated
variate stress.
One explanation for the variable findings between previous work and this study can be attributed
to the paradigms used to evaluate the VEGF/receptor system in the neurogenic bladder.
Cheppudira et al., implemented a drug-based approach to replicate interstitial cystitis in rats
(2008), while Lindholm and Sato administered surgical injuries to the CNS and PNS in rats
(2017; 2017). In contrast, this study examined cystitis through the psychogenic stress paradigm.
Collectively, these studies represent how the VEGF/receptor system responds to different
approaches to replicate interstitial cystitis in the urinary bladder and injury to the DRGs. Thus,
findings from this study contribute novel findings of how VEGF/receptor system responds to
psychogenic stress-induced bladder inflammation, in which the system was more responsive in
the urinary bladder and DRG in male mice, and the spinal cord and DRGs in female mice.
Another explanation for these results can be attributed to the animal model. The studies
discussed previously used rats to examine the VEGF/receptor system (Cheppudira, 2008;
Lindholm, 2017; Sato 2017), while the animal model for this study comprised mice. Thus, it is
also likely that animal model-based differences contributed to the contrasting results of these
experiments in comparison to previous work. Furthermore, there is a higher prevalence of rat
models that have been used to explore the implications of psychogenic stress using repeated
variate stress (King, 2017; Merrill, 2013 Hammack, 2009). Recently, the Vizzard lab has begun
to extend the number of days mice are exposed to RVS. Researchers in this lab have found that
functional data supports the duration of 7 days of RVS as an effective length of time to alter
bladder function in rats. However, mice appear to be more resilient to chronic variate stress.
Current unpublished functional data suggests that changes to the urinary bladder function are
evident in mice after extending exposure to RVS up to at least 14 days. Considering this finding,
a replication of this study is recommended to observe changes to expression, function and
regulation in neurogenic bladders of mice that have been exposed to 14 days of RVS.
Based on previous research, VEGF/receptor signaling pathways are present in the neural
circuitry that responds to injury in the CNS or PNS, and in the urinary bladder. Our current study
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confirmed that VEGF and its receptors are present in the urinary bladder as well as the neural
pathways that control bladder reflexes. The findings from this research also contribute novel
findings to the literature of the urinary bladder pathophysiology by examining the expression,
regulation and function of the VEGF/receptor system in the urinary bladder in response to
psychogenic stress-induced cystitis. The contribution of the VEGF/receptor system to the
development of interstitial cystitis remains unknown. However, previous research in conjunction
with this study suggest that the model of cystitis used may trigger a different response by the
VEGF/receptor system in the neurogenic bladder.
Functional role of the VEGF/receptor system in Urinary Bladder
Studying effects of potential pharmaceutical treatments to target bladder function disorders such
as interstitial cystitis has been integral to understanding the pathophysiology of the urinary
bladder. Mice exposed to social stress, for example, exhibited traits such as decreased
intermicturition intervals and void volumes, which were corrected following TRPV1 blockade in
mice undergoing conscious cystometry (Mingin et al., 2015). In another study conducted by the
Vizzard lab, mice exposed to the repeated variate stress model exhibited decreased bladder
capacity and increased voiding frequency, which were reversed following administration of
TRPV4 blockade (Merrill & Vizzard, 2014). Previous work also confirmed the validity of the
RVS model to replicate bladder overactivity ascribed to urinary bladder inflammation (Merrill &
Vizzard, 2014).
In these experiments, we examined the functional role of the VEGF/receptor system in the
urinary bladder using Ki 8751, a known VEGFR2 antagonist. Control and RVS-exposed mice
were kept unrestrained in their chambers as they underwent conscious cystometry. The
urodynamic measurements collected included a pre-infusion phase (where mice acclimated to
their chambers) and a post infusion phase (after a 30-minute period, where Ki 8751 infusion was
administered). These experiments examined the effect of Ki 8751 by comparing the urodynamic
measurements collected from pre-infusion phase to the post-infusion data. There were no
changes observed to voiding frequency or bladder capacity for both control and RVS-exposed
male mice following the VEGFR2 blockade. Similarly, female mice in both treatment groups did
not exhibit change to bladder function after receiving an infusion of the VEGFR2 antagonist. In
summary, administering Ki 8751 did not alter normal bladder function in both male and female
control mice. Likewise, the reversal of bladder dysfunction was not observed in male and female
mice exposed to repeated variate stress.
One limitation to the conscious cystometry performed is the reliability of the void volume, which
is a measure of voiding frequency. In mice, the void outputs did not consistently hit the pan,
which calculates the output per void cycle, as the urine can get stuck on the wire platform. While
each void cycle was confirmed using other measures such as bladder pressure, the void volume
was not always be accounted for by the cystometrogram. Even so, the void volumes were
unchanged for both treatment groups in male and female mice. Furthermore, the intermicturition
intervals, another measure to assess voiding frequency, were also insignificant. To overcome this
limitation, we used the void volume data, accompanied by the reliability of the intermicturition
intervals, to assess our voiding frequency paradigm as a function of bladder activity.
23

Compared to the TRPV1 and TRPV4 blockades, the VEGFR2 blockade may not be an effective
treatment to restore bladder overactivity following exposure to psychogenic stressors. One
explanation for this finding can be made using QPCR results for both male and female RVSexposed mice. As discussed earlier, VEGFR2 was not responsive to RVS in the urinary bladders
of both sexes. We thereby concluded that VEGFR2 was not regulated in mice exposed to RVS.
This finding supports the lack of a functional role of VEGFR2, observed in bladder activity
following administration of Ki 8751. As mentioned earlier, the increased levels of Nrp-2
transcript levels in the male detrusor was the only evidence regulation in the urinary bladder,
following exposure to repeated variate stress. Thus, one expansion to this study includes
examining the functional role of Nrp-2 in psychogenic stress-induced bladder inflammation by
infusing a pharmaceutical blockade of Nrp-2 in the urinary bladder.
Conclusion
Collectively, the results derived from this study demonstrate that VEGF/receptor transcripts are
present in the neural pathways controlling urinary bladder reflexes and in the urinary bladder.
Additionally, the regulation of VEGF/receptor transcript expression in mice exposed to repeated
variate stress was observed in the bladder and DRG in males, and in the spinal cord and DRG in
females; thereby implicating that different parts of the micturition reflex system are more
responsive to RVS. Functional studies suggest the VEGFR2 blockade may not be an effective
treatment to restore chronic variate stress-induced bladder dysfunction. Further studies to expand
the literature of VEGF and its relationship with psychogenic stress is recommended, including
the functional contribution of the Neuropilin-2 receptor to bladder reflexes in mice exposed to
RVS using pharmacologic agents. Future studies should also consider replicating this research
study in mice exposed to an extended period of RVS, up to 14 days or more.
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